{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:06:38Z","timestamp":1784297198111,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,17]]},"DOI":"10.7759\/cureus.112849","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T13:36:46Z","timestamp":1784295406000},"source":"Crossref","is-referenced-by-count":0,"title":["Cutting-Edge Cardiology: Individualizing Antiplatelet Therapy for Optimal Acute Coronary Syndrome Outcomes"],"prefix":"10.7759","author":[{"given":"Gilbert","family":"Abounader","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Bejjani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said  M","family":"Chaaban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sobhi","family":"Dada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Fakhoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malek","family":"Hamade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hobeika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Iskandarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malek","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdallah G","family":"Rebeiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"El Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa","family":"Hallal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maroun","family":"Soueidy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jscai.2024.102510","article-title":"Dual antiplatelet therapy duration following percutaneous coronary intervention: Time for a change","volume":"4","author":"Kereiakes DJ","year":"2025","unstructured":"Kereiakes DJ. Dual antiplatelet therapy duration following percutaneous coronary intervention: Time for a change. J Soc Cardiovasc Angiogr Interv. 2025, 4:102510. 10.1016\/j.jscai.2024.102510","journal-title":"J Soc Cardiovasc Angiogr Interv"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.05.062","article-title":"Bleeding and ischemic risks of ticagrelor\u00a0monotherapy after coronary\u00a0interventions","volume":"82","author":"Mendieta G","year":"2023","unstructured":"Mendieta G, Mehta S, Baber U, et al.. Bleeding and ischemic risks of ticagrelor\u00a0monotherapy after coronary\u00a0interventions. J Am Coll Cardiol. 2023, 82:687-700. 10.1016\/j.jacc.2023.05.062","journal-title":"J Am Coll Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.07.031","article-title":"Comparison of antiplatelet monotherapies after percutaneous coronary intervention according to clinical, ischemic, and bleeding risks","volume":"82","author":"Yang S","year":"2023","unstructured":"Yang S, Kang J, Park KW, et al.. Comparison of antiplatelet monotherapies after percutaneous coronary intervention according to clinical, ischemic, and bleeding risks. J Am Coll Cardiol. 2023, 82:1565-78. 10.1016\/j.jacc.2023.07.031","journal-title":"J Am Coll Cardiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001309","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: A report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"151","author":"Rao SV","year":"2025","unstructured":"Rao SV, O'Donoghue ML, Ruel M, et al.. 2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: A report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2025, 151:e771-862. 10.1161\/CIR.0000000000001309","journal-title":"Circulation"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-023-01126-x","article-title":"The pandemic of coronary heart disease in the Middle East and North Africa: What clinicians need to know","volume":"25","author":"Manla Y","year":"2023","unstructured":"Manla Y, Almahmeed W. The pandemic of coronary heart disease in the Middle East and North Africa: What clinicians need to know. Curr Atheroscler Rep. 2023, 25:543-57. 10.1007\/s11883-023-01126-x","journal-title":"Curr Atheroscler Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S97252","article-title":"Prevalence and correlates of coronary heart disease: First population-based study in Lebanon","volume":"12","author":"Zeidan RK","year":"2016","unstructured":"Zeidan RK, Farah R, Chahine MN, Asmar R, Hosseini H, Salameh P, Pathak A. Prevalence and correlates of coronary heart disease: First population-based study in Lebanon. Vasc Health Risk Manag. 2016, 12:75-84. 10.2147\/VHRM.S97252","journal-title":"Vasc Health Risk Manag"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.gheart.2018.03.001","article-title":"Worsening of the cardiovascular profile in a developing country: The Greater Beirut Area Cardiovascular Cohort","volume":"13","author":"Isma'eel HA","year":"2018","unstructured":"Isma'eel HA, Almedawar MM, Breidy J, et al.. Worsening of the cardiovascular profile in a developing country: The Greater Beirut Area Cardiovascular Cohort. Glob Heart. 2018, 13:275-83. 10.1016\/j.gheart.2018.03.001","journal-title":"Glob Heart"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne RA","year":"2023","unstructured":"Byrne RA, Rossello X, Coughlan JJ, et al.. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J. 2023, 44:3720-826. 10.1093\/eurheartj\/ehad191","journal-title":"Eur Heart J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000404","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A Report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines: An update of the 2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention, 2011 ACCF\/AHA guideline for coronary artery bypass graft surgery, 2012 ACC\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC\/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery","volume":"134","author":"Levine GN","year":"2016","unstructured":"Levine GN, Bates ER, Bittl JA, et al.. 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A Report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines: An update of the 2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention, 2011 ACCF\/AHA guideline for coronary artery bypass graft surgery, 2012 ACC\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC\/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation. 2016, 134:e123-55. 10.1161\/CIR.0000000000000404","journal-title":"Circulation"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual antiplatelet therapy after PCI in patients at high bleeding risk","volume":"385","author":"Valgimigli M","year":"2021","unstructured":"Valgimigli M, Frigoli E, Heg D, et al.. Dual antiplatelet therapy after PCI in patients at high bleeding risk. N Engl J Med. 2021, 385:1643-55. 10.1056\/NEJMoa2108749","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri L","year":"2014","unstructured":"Mauri L, Kereiakes DJ, Yeh RW, et al.. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014, 371:2155-66. 10.1056\/NEJMoa1409312","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv531","article-title":"Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: Insights from PEGASUS-TIMI 54","volume":"37","author":"Bonaca MP","year":"2016","unstructured":"Bonaca MP, Bhatt DL, Steg PG, et al.. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: Insights from PEGASUS-TIMI 54. Eur Heart J. 2016, 37:1133-42. 10.1093\/eurheartj\/ehv531","journal-title":"Eur Heart J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908077","article-title":"Ticagrelor in patients with stable coronary disease and diabetes","volume":"381","author":"Steg PG","year":"2019","unstructured":"Steg PG, Bhatt DL, Simon T, et al.. Ticagrelor in patients with stable coronary disease and diabetes. N Engl J Med. 2019, 381:1309-20. 10.1056\/NEJMoa1908077","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca MP","year":"2015","unstructured":"Bonaca MP, Bhatt DL, Cohen M, et al.. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015, 372:1791-800. 10.1056\/NEJMoa1500857","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin L","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, et al.. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009, 361:1045-57. 10.1056\/NEJMoa0904327","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott SD","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH, et al.. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007, 357:2001-15. 10.1056\/NEJMoa0706482","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.818215","article-title":"Comparison of clinical outcomes between ticagrelor and clopidogrel in acute coronary syndrome: A comprehensive meta-analysis","volume":"8","author":"Sun M","year":"2021","unstructured":"Sun M, Cui W, Li L. Comparison of clinical outcomes between ticagrelor and clopidogrel in acute coronary syndrome: A comprehensive meta-analysis. Front Cardiovasc Med. 2021, 8:818215. 10.3389\/fcvm.2021.818215","journal-title":"Front Cardiovasc Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-022-01354-5","article-title":"Cardiovascular outcomes observed with ticagrelor versus clopidogrel in type 2 diabetes mellitus patients with acute coronary syndrome: A meta-analysis","volume":"14","author":"Jiang Z","year":"2023","unstructured":"Jiang Z, Liu L, Bundhun PK. Cardiovascular outcomes observed with ticagrelor versus clopidogrel in type 2 diabetes mellitus patients with acute coronary syndrome: A meta-analysis. Diabetes Ther. 2023, 14:387-99. 10.1007\/s13300-022-01354-5","journal-title":"Diabetes Ther"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet JP","year":"2021","unstructured":"Collet JP, Thiele H, Barbato E, et al.. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021, 42:1289-367. 10.1093\/eurheartj\/ehaa575","journal-title":"Eur Heart J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"Mehran R","year":"2019","unstructured":"Mehran R, Baber U, Sharma SK, et al.. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med. 2019, 381:2032-42. 10.1056\/NEJMoa1908419","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: The TICO randomized clinical trial","volume":"323","author":"Kim BK","year":"2020","unstructured":"Kim BK, Hong SJ, Cho YH, et al.. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: The TICO randomized clinical trial. JAMA. 2020, 323:2407-16. 10.1001\/jama.2020.7580","journal-title":"JAMA"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2021.5244","article-title":"Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: The STOPDAPT-2 ACS randomized clinical trial","volume":"7","author":"Watanabe H","year":"2022","unstructured":"Watanabe H, Morimoto T, Natsuaki M, et al.. Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: The STOPDAPT-2 ACS randomized clinical trial. JAMA Cardiol. 2022, 7:407-17. 10.1001\/jamacardio.2021.5244","journal-title":"JAMA Cardiol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx175","article-title":"Benefit of switching dual antiplatelet therapy after acute coronary syndrome: The TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study","volume":"38","author":"Cuisset T","year":"2017","unstructured":"Cuisset T, Deharo P, Quilici J, et al.. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: The TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J. 2017, 38:3070-8. 10.1093\/eurheartj\/ehx175","journal-title":"Eur Heart J"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01445-8","article-title":"Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): An investigator-initiated, open-label, multicentre, non-inferiority, randomised trial","volume":"398","author":"Kim CJ","year":"2021","unstructured":"Kim CJ, Park M-W, Kim MC, et al.. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): An investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. Lancet. 2021, 398:1305-16. 10.1016\/S0140-6736(21)01445-8","journal-title":"Lancet"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32155-4","article-title":"Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): A randomised, open-label, multicentre trial","volume":"390","author":"Sibbing D","year":"2017","unstructured":"Sibbing D, Aradi D, Jacobshagen C, et al.. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): A randomised, open-label, multicentre trial. Lancet. 2017, 390:1747-57. 10.1016\/S0140-6736(17)32155-4","journal-title":"Lancet"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1907096","article-title":"A genotype-guided strategy for oral P2Y(12) inhibitors in primary PCI","volume":"381","author":"Claassens DM","year":"2019","unstructured":"Claassens DM, Vos GJ, Bergmeijer TO, et al.. A genotype-guided strategy for oral P2Y(12) inhibitors in primary PCI. N Engl J Med. 2019, 381:1621-31. 10.1056\/NEJMoa1907096","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.017109","article-title":"Pooled analysis of bleeding, major adverse cardiovascular events, and all-cause mortality in clinical trials of time-constrained dual-antiplatelet therapy after percutaneous coronary intervention","volume":"9","author":"McClure JD","year":"2020","unstructured":"McClure JD, Ramsay JC, Berry C. Pooled analysis of bleeding, major adverse cardiovascular events, and all-cause mortality in clinical trials of time-constrained dual-antiplatelet therapy after percutaneous coronary intervention. J Am Heart Assoc. 2020, 9:e017109. 10.1161\/JAHA.120.017109","journal-title":"J Am Heart Assoc"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvab068","article-title":"Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: A meta-analysis","volume":"8","author":"Tavenier AH","year":"2022","unstructured":"Tavenier AH, Mehran R, Chiarito M, et al.. Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: A meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2022, 8:492-502. 10.1093\/ehjcvp\/pvab068","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00473-2","article-title":"Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): A randomised, placebo-controlled, double-blind clinical trial","volume":"403","author":"Ge Z","year":"2024","unstructured":"Ge Z, Kan J, Gao X, et al.. Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): A randomised, placebo-controlled, double-blind clinical trial. Lancet. 2024, 403:1866-78. 10.1016\/S0140-6736(24)00473-2","journal-title":"Lancet"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.123.066943","article-title":"Stopping aspirin within 1 month after stenting for ticagrelor monotherapy in acute coronary syndrome: The T-PASS randomized noninferiority trial","volume":"149","author":"Hong SJ","year":"2024","unstructured":"Hong SJ, Lee SJ, Suh Y, et al.. Stopping aspirin within 1 month after stenting for ticagrelor monotherapy in acute coronary syndrome: The T-PASS randomized noninferiority trial. Circulation. 2024, 149:562-73. 10.1161\/CIRCULATIONAHA.123.066943","journal-title":"Circulation"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom JW","year":"2017","unstructured":"Eikelboom JW, Connolly SJ, Bosch J, et al.. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017, 377:1319-30. 10.1056\/NEJMoa1709118","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega JL","year":"2012","unstructured":"Mega JL, Braunwald E, Wiviott SD, et al.. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012, 366:9-19. 10.1056\/NEJMoa1112277","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/508248-cutting-edge-cardiology-individualizing-antiplatelet-therapy-for-optimal-acute-coronary-syndrome-outcomes","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T13:36:47Z","timestamp":1784295407000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/508248-cutting-edge-cardiology-individualizing-antiplatelet-therapy-for-optimal-acute-coronary-syndrome-outcomes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":32,"URL":"https:\/\/doi.org\/10.7759\/cureus.112849","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,17]]}}}